Today, fool.com health-care analysts Brenton Flynn and David Williamson discuss one kidney cancer drug with interesting recent data. GlaxoSmithKline's drug was proven as effective as the drug's nearest rival.
While this is certainly good news, David cautions that the kidney cancer drug space is becoming increasingly competitive, and he doesn't believe Glaxo's drug is poised to take the sector crown any time soon.
When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
The article 1 Stock Gunning for the Kidney Cancer Crown originally appeared on Fool.com.
Brenton Flynn and Dave Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.